Compare TTRX & ECBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TTRX | ECBK |
|---|---|---|
| Founded | 2015 | 1919 |
| Country | United States | United States |
| Employees | 2 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 281.2M | 176.0M |
| IPO Year | N/A | 2022 |
| Metric | TTRX | ECBK |
|---|---|---|
| Price | $8.17 | $20.41 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | ★ 128.5K | 5.6K |
| Earning Date | 05-31-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 95.83 |
| EPS | N/A | ★ 0.38 |
| Revenue | N/A | ★ $598,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $52.39 |
| Revenue Growth | N/A | ★ 3.64 |
| 52 Week Low | $2.57 | $14.83 |
| 52 Week High | $11.69 | $20.76 |
| Indicator | TTRX | ECBK |
|---|---|---|
| Relative Strength Index (RSI) | 47.75 | 55.27 |
| Support Level | $4.40 | $17.76 |
| Resistance Level | $11.69 | $20.76 |
| Average True Range (ATR) | 1.04 | 0.34 |
| MACD | -0.22 | -0.07 |
| Stochastic Oscillator | 4.52 | 57.93 |
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.
ECB Bancorp Inc operates as a bank holding company. The firm, through its subsidiary, engages in business consisting of taking deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential real estate loans, commercial real estate, multifamily real estate loans, construction and land loans, and home equity lines of credit.